Previous Close | 0.7800 |
Open | 0.8080 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.6700 - 0.8080 |
52 Week Range | 0.0680 - 1.8620 |
Volume | |
Avg. Volume | 4,416 |
Market Cap | 9.733M |
Beta (5Y Monthly) | -0.35 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0900 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Niagara Falls, NY, June 24, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging device systems and clinical services company, is pleased to announce that Christopher Reilly has joined Positron to lead the Company’s PET-CT Services and Systems Sales. Through a career spanning over three decades, Mr. Reilly has acquired vast expertise and industry knowledge in all aspects of SPECT imaging systems, services, pharmaceuticals and pra
Niagara Falls, NY , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging device systems and clinical services company, is pleased to announce today that the Company has retained Medical Device Academy ”MDA”) as its consultant for the Company’s new PET/CT device 510K submission with the Food and Drug Administration (“FDA”). Positron will be applying for new device approval to market and sell its PET/CT device in the Unite
Niagara Falls, NY, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging company specializing in the field of cardiac Positron Emission Tomography (“PET”) imaging systems and clinical services, is pleased to issue today the following shareholder letter below. The letter is also available on the Company’s website at: http://www.positron.com/. Positron Corporation Shareholder Letter Dear Positron Shareholders, In considerat